John DiPersio – VJRegenMed

CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT

Anya Kerkache — Thu, 09 Mar 2023 11:31:49 +0000

John DiPersio, MD, PhD, Washington University School of Medicine, St. Louis, MO, shares the rationale and results of a first-in-human clinical trial evaluating the safety of trem-cel (formerly VOR33), a CD33 CRISPR/Cas9 gene-edited donor allograft designed to prevent relapse in patients with acute myeloid leukemia (AML) undergoing hematopoietic stem cell transplantation (HSCT; NCT04849910). Results from the first two patients transplanted with trem-cel indicated neutrophil engraftment and a similar platelet recovery when compared to patients who received non-edited CD34-selected grafts. Treatment with gemtuzumab ozogamicin (GO) in one of the recipients did not result in a change in blood counts, suggesting that the target was effectively eliminated on the recipient’s stem cells and that GO would then only target residual leukemia cells expressing CD33. The ability of this strategy to induce long-term remission and to effectively eliminate all residual leukemia cells remains to be confirmed. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Immunotherapy for T-cell malignancies

admin_vjr_user — Tue, 03 Nov 2020 17:39:54 +0000

John DiPersio, MD, PhD, Washington University, St. Louis, MO, discusses recent advances in the use of cellular therapies for T-cell malignancies including T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin lymphoma, including using CRISPR gene editing to eliminate the target on the effector T-cell to prevent fratricide, as well as using off-the-shelf allogeneic T-cells to prevent contamination of tumor cells. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Next questions in CAR-based therapies

admin_vjr_user — Tue, 03 Nov 2020 17:39:54 +0000

John DiPersio, MD, PhD, of Washington University, St. Louis, MO, outlines the next questions in CAR-based therapies and new approaches to improving the efficacy of CAR T-cells including generating CAR T-cells that can target multiple antigens, as well as improving the persistence of CAR T-cells in vivo. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).